 Home > Medical News > Latest Medical News > The State Food and Drug Administration approves the world's first ARNI hypertension indication

The State Food and Drug Administration approves the world's first ARNI hypertension indication

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

androgen receptor inhibitor

suboxone drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The State Food and Drug Administration approves the world's first ARNI hypertension indication

The State Food and Drug Administration approved the world's first ARNI hypertension indication The State Food and Drug Administration approved the world's first ARNI hypertension indication

Hypertension is the primary risk factor for cardiovascular events.

ARNI is an innovative drug that acts on both the renin-angiotensin-aldosterone (RAAS) system and the natriuretic peptide system, by enhancing the blood pressure regulation of the natriuretic peptide system while inhibiting RAAS to achieve multi-channel blood pressure reduction, namely It can strengthen the human body's blood pressure system while restraining the pressure boost system, exerting the effect of large drop, fast onset, and 24-hour pressure control.

The results of a phase III clinical study led by Professor Yong Huo from Peking University First Hospital and vice chairman of the Chinese Cardiovascular Health Alliance showed that the blood pressure lowering effect of sacubitril and valsartan after 8 weeks of treatment was significantly better than that of ARB drugs In the control group with the best antihypertensive effect, it can significantly improve the patient's blood pressure compliance rate.

In addition, a number of domestic and foreign studies have also shown that regardless of the level of blood pressure in hypertensive patients and whether they are associated with risk factors or heart and kidney damage, sacubitril and valsartan show general antihypertensive effects.

Professor Yong Huo said: "my country's hypertension management is facing multiple challenges such as low compliance rate, high proportion of comorbidities, and increased target organ damage.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.